Skip to main navigation Skip to search Skip to main content

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062

  • Hironaga Satake
  • , Keun Wook Lee
  • , Hyun Cheol Chung
  • , Jeeyun Lee
  • , Kensei Yamaguchi
  • , Jen Shi Chen
  • , Takaki Yoshikawa
  • , Kenji Amagai
  • , Kun Huei Yeh
  • , Masahiro Goto
  • , Yee Chao
  • , Ka On Lam
  • , Shi Rong Han
  • , Shinichi Shiratori
  • , Sukrut Shah
  • , Kohei Shitara
  • Kobe City Medical Center General Hospital
  • Seoul National University
  • Yonsei University
  • Japanese Foundation for Cancer Research
  • Chang Gung Memorial Hospital
  • National Cancer Center Japan
  • Ibaraki Prefectural Central Hospital
  • National Taiwan University
  • Osaka Medical and Pharmaceutical University
  • Veterans General Hospital-Taipei
  • The University of Hong Kong
  • Universidad Nacional de Córdoba
  • Merck
  • Nagoya University

Research output: Contribution to journal › Article › peer-review

15   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science